We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
-$69.3M
Cap. Flow %
-1.88%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Consumer Discretionary 6.51%
3 Financials 0.7%
4 Materials 0.48%
5 Consumer Staples 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBTX
76
Nanobiotix
NBTX
$1.92B
$8.1M 0.22%
1,000,000
– –
ADAG
77
Adagene
ADAG
$246M
$8.07M 0.22%
1,000,000
– –
OVID icon
78
Ovid Therapeutics
OVID
$427M
$8.03M 0.22%
2,500,000
– –
SPRO icon
79
Spero Therapeutics
SPRO
$68.9M
$8.01M 0.22%
500,000
– –
TIL icon
80
Instil Bio
TIL
$49M
$7.7M 0.21%
22,500
– –
HARP
81
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$7.55M 0.2%
100,000
– –
MRSN
82
DELISTED
Mersana Therapeutics
MRSN
$7.46M 0.2%
48,000
– –
ZYME icon
83
Zymeworks
ZYME
$1.62B
$7.38M 0.2%
450,000
– –
OMEG
84
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.33M 0.2%
750,000
– –
XLO icon
85
Xilio Therapeutics
XLO
$59.8M
$7.2M 0.2%
+32,143
New +$7.66M
IMCR icon
86
Immunocore
IMCR
$1.7B
$6.85M 0.19%
200,000
– –
IMUX icon
87
Immunic
IMUX
$178M
$6.7M 0.18%
70,000
– –
YMAB
88
DELISTED
Y-mAbs Therapeutics
YMAB
$6.48M 0.18%
400,000
– –
VOR icon
89
Vor Biopharma
VOR
$1.06B
$6.39M 0.17%
27,500
– –
DYN icon
90
Dyne Therapeutics
DYN
$4.15B
$6.24M 0.17%
525,000
– –
SANA icon
91
Sana Biotechnology
SANA
$882M
$6.19M 0.17%
400,000
– –
CRIS icon
92
Curis
CRIS
$9.71M
$6.19M 0.17%
3,250
– –
CRBU icon
93
Caribou Biosciences
CRBU
$146M
$6.12M 0.17%
405,347
– –
EVLO
94
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$6.07M 0.16%
50,000
– –
STOK icon
95
Stoke Therapeutics
STOK
$1.84B
$6M 0.16%
250,000
– –
RNAM
96
DELISTED
Avidity Biosciences
RNAM
$5.94M 0.16%
250,000
+107,500
+75% +$2.57M
ORIC icon
97
Oric Pharmaceuticals
ORIC
$1.17B
$5.88M 0.16%
400,000
– –
NEXI
98
DELISTED
NexImmune, Inc. Common Stock
NEXI
$5.53M 0.15%
48,000
– –
LYEL icon
99
Lyell Immunopharma
LYEL
$318M
$5.42M 0.15%
35,000
– –
ADVM
100
DELISTED
Adverum Biotechnologies
ADVM
$5.28M 0.14%
300,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.